openPR Logo
Press release

Rare Inflammatory Disease Treatment Market CAGR to Grow at 4.4%

06-01-2018 11:06 AM CET | Health & Medicine

Press release from: Future Market Insights

Rare Inflammatory Disease Treatment Market CAGR to Grow at 4.4%

With mounting instances of genetic diseases, demand for therapeutic measures have witnessed a hike, as no effective procedures exist that provide effective treatment of genetic or rare inflammatory diseases. Chromosomal changes primarily influence prevalence of these diseases. In a bid to curtail the disease prevalence, several pharmaceutical industries have been taking efforts to make advancements in relevant drugs as well as therapeutic methods. For example, new treatment options are being developed by researchers for geriatric and pediatric patients suffering from Still’s disease, which is a rare disease linked with the inflammation of joints.

Doctors are stepping up their efforts by creating awareness among the patients with regard to benefits of anti-inflammatory drugs, which have been deemed effective in the prevention and control of rare inflammatory diseases. Currently, there is rapid increase in the demand for authorized effective treatments of the rare inflammatory diseases. The OOPD (Office of Orphan Products Development) has been offering incentives to drug companies, supporting the development of treatment methods for these diseases. National Institutes of Health (NIH) are providing immense support for improving patients’ health, by focusing mainly on the development of new treatment methods. Collaborative projects are being initiated by NIH in order to examine the common causes and effects of related diseases.

Significant findings from report show that the global market for rare inflammatory disease treatment will increase at an assessed 4.4% CAGR during the forecast period, 2017-2026. The report also anticipates that by 2026-end, rare inflammatory disease treatment worth nearly US$ 15,960.8Mn will be witnessed across the globe.

Request to Sample Report -

Increasing Inflammatory & Autoimmune Diseases to Create Opportunities for New Therapies

Several group of scientists have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases, which in turn is creating new ways of development for therapies. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.

Moreover, the occurrence of inflammatory and autoimmune diseases is increasing on a rapid pace. Globally, an approximate number of 125 million populace are affected by psoriasis and around 100 million by rheumatoid arthritis annually. The presence of inflammatory bowel infections such as ulcerative colitis and Crohn’s disease is increasing at an alarming rate in formerly unaffected fragments of the world.

Key Takeaways from Rare Inflammatory Disease Treatment Market Report for Estimated Period, 2017-2026

In terms of revenue, North America will remain the largest market for rare inflammatory disease treatment market, closely followed by Europe. Nearly half value share of the market is held by rare inflammatory disease treatment sales in North America and Europe collectively. APEJ will also bolt onto a largest market revenue share, by registering a relatively faster expansion than Europe in the market through 2026.

Request Report TOC @

On the basis of indication, ulcerative colitis are likely to remain considerably larger than that of the other segments.

The lion’s share in the global market for rare inflammatory disease treatment is contributed by biologics segment.

Oral care & Hospital Pharmacies will observe fastest growth during the forecast period.

Key market players outlined by the report is inclusive of Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Inc., Novartis AG, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, and Swedish Orphan Biovitrum AB.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Inflammatory Disease Treatment Market CAGR to Grow at 4.4% here

News-ID: 1068286 • Views: 174

More Releases from Future Market Insights

How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring

All 5 Releases

More Releases for Inflammatory

Digital Landscape: Inflammatory Bowel Disease Market
The Digital Landscape Inflammatory Bowel Disease market report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn’s disease and ulcerative colitis (UC). Key Highlights - US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen was the most active competitor in the branded and social media spaces in 2017. Branded activity also seen from pipeline
Anti-Inflammatory Peptides Market to Develop Rapidly by 2015 – 2023
Anti Inflammatory Peptides Market: Overview Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal’s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases. Download PDF Brochure of
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2 …
ReportsWorldwide has announced the addition of a new report title Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline landscape. Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as
Anti-Inflammatory Therapeutics Market - Positive long-term growth outlook 2019
Also known as non-steroidal anti- inflammatory drugs, anti-inflammatory therapeutics help in easing acute and mild chronic pain. Be it migraines and headaches, rheumatic arthritis, sprains, or even menstrual pain, anti- inflammatory therapeutics can provide faster relief as compared with other drugs. They are capable of lowering the levels of prostaglandins, the chemicals responsible for inflammation, reducing pain and swelling. Aspirin, acelofenac, celecoxib, etoricoxib, acemetacin, etodolac, ibuprofen, Meloxicam, tenoxicam, dexketoprofen, fenoprofen, sulindac,
Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Size and Research Repor …
Market Research Hub has recently announced the report on “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)”. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Review, H1 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape. Request a Free Sample Report: Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and